Physician profile
Robert Ebeling
NPI 1285896936
$285.65
in general payments reported to CMS, 2019-2025
13 companies · $66.07 in 2025
The $66.07 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.62 · 2020: $76.03 · 2021: $39.23 · 2022: $26.70 · 2025: $66.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $60.92 | 2020-2025 | Imjudo |
| Boston Scientific Corporation | $35.94 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $26.70 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.08 | 2025 | Onivyde |
| Blue Earth Diagnostics | $20.33 | 2021 | |
| Merck Sharp & Dohme LLC | $18.59 | 2025 | Keytruda Qlex, Welireg, Keytruda |
| E.R. Squibb & Sons, L.L.C. | $16.84 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.29 | 2019 | |
| Astellas Pharma US INC | $14.76 | 2020 | |
| Eisai INC. | $14.17 | 2019 | |
| Janssen Biotech, INC. | $13.26 | 2019 | |
| Tactile Systems Technology INC | $12.41 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ebeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.